- Home
- ATEN vs NUVB Comparison
ATEN vs NUVB Comparison
Compare ATEN & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATEN
- NUVB
- Stock Information
- Founded
- ATEN 2004
- NUVB 2018
- Country
- ATEN United States
- NUVB United States
- Employees
- ATEN N/A
- NUVB N/A
- Industry
- ATEN EDP Services
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- ATEN Technology
- NUVB Health Care
- Exchange
- ATEN Nasdaq
- NUVB Nasdaq
- Market Cap
- ATEN 1.3B
- NUVB 1.1B
- IPO Year
- ATEN 2014
- NUVB N/A
- Fundamental
- Price
- ATEN $18.12
- NUVB $3.65
- Analyst Decision
- ATEN Strong Buy
- NUVB Strong Buy
- Analyst Count
- ATEN 4
- NUVB 7
- Target Price
- ATEN $21.50
- NUVB $8.43
- AVG Volume (30 Days)
- ATEN 670.4K
- NUVB 6.7M
- Earning Date
- ATEN 11-04-2025
- NUVB 11-05-2025
- Dividend Yield
- ATEN 1.32%
- NUVB N/A
- EPS Growth
- ATEN 21.29
- NUVB N/A
- EPS
- ATEN 0.69
- NUVB N/A
- Revenue
- ATEN $276,445,000.00
- NUVB $14,355,000.00
- Revenue This Year
- ATEN $10.53
- NUVB $332.80
- Revenue Next Year
- ATEN $7.41
- NUVB $360.12
- P/E Ratio
- ATEN $26.28
- NUVB N/A
- Revenue Growth
- ATEN 11.04
- NUVB 900.35
- 52 Week Low
- ATEN $13.81
- NUVB $1.54
- 52 Week High
- ATEN $21.90
- NUVB $4.09
- Technical
- Relative Strength Index (RSI)
- ATEN 51.66
- NUVB 61.90
- Support Level
- ATEN $17.76
- NUVB $3.00
- Resistance Level
- ATEN $18.77
- NUVB $3.88
- Average True Range (ATR)
- ATEN 0.39
- NUVB 0.24
- MACD
- ATEN 0.02
- NUVB 0.02
- Stochastic Oscillator
- ATEN 40.65
- NUVB 68.59
About ATEN A10 Networks Inc.
A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.